FindTrial
Sign In

Comparing Ormeloxifene With Norethisterone In Treatment For Uterine Bleeding Without Any Organic Cause

Comparision Of Effectiveness Of Ormeloxifene With Norethisterone In Treatment For Dub In All Age Groups

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025630
Enrollment
120
Registered
2020-06-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N939- Abnormal uterine and vaginal bleeding, unspecified

Interventions

Intervention1: Oral Ormeloxifene: Drug: Ormeloxifene Dose: 60mg For 60 Patients Frequency: Twice Per Week For 3 Months Followed By Once Per Week For Next 3 Months Control Intervention1: Oral Norethi

Sponsors

Dr Manogna Chukka
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Females Having Complain Of Heavy Menstrual Blood Loss

Exclusion criteria

Exclusion criteria: 1 Haemodynamically Unstable Patients 2 Organic Pelvic Pathology

Design outcomes

Primary

MeasureTime frame
Both The Comparing Drugs Are Not Same In EfficacyTimepoint: My Period Of Study Is Of 18 Months—

Secondary

MeasureTime frame
Unwanted Blood Loss Can Be Prevented, Eventually Reducing AnaemiaTimepoint: My Period Of Study Is Of 18 Months—

Countries

India

Contacts

Public ContactDr Manogna Chukka

vinayaka missions medical college

muvva93@gmail.com8247794673

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026